Consequently, evidence of a FXR-mediated decrease in hepatic lipid accumulation and improved insulin sensitivity is the basis for the use of its agonists in NAFLD treatment. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.